Information
Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technologySAN JOSE, Calif., Feb. 23, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a
Original sourceAI Summary
Anixa Biosciences announced that Dr. Jose Conejo-Garcia will present their innovative CAR-T therapy at the upcoming SCTR 2026 Retreat. His discussion on the Phase 1 trial of lira-cel is likely to boost investor confidence and could attract interest in Anixa’s disease-fighting capabilities.
Sentiment Rationale
Dr. Conejo-Garcia’s involvement adds credibility; historical presentations have positively impacted stocks.
Trading Thesis
ANIX is a buy due to upcoming presentations and potential for increased investor interest.
Market-Moving
- Keynote presentation could generate positive media coverage for Anixa.
- Increased visibility at the retreat may attract new partnerships and funding.
- Any updates on the Phase 1 trial could drive stock price higher.
- Successful trial results or collaborations could catalyze a significant price increase.
Key Facts
- Dr. Conejo-Garcia will keynote SCTR Institute 2026 Retreat focused on cell therapies.
- Presentation includes Anixa's Phase 1 trial of lira-cel for ovarian cancer.
- Lira-cel targets ovarian cancer cells using FSHR-mediated CAR-T technology.
- Anixa continues collaboration with Moffitt Cancer Center for cancer immunotherapy.
- Innovations discussed may enhance Anixa's visibility and partnerships in the industry.
Companies Mentioned
- Moffitt Cancer Center: Collaborative partner in developing Anixa's CAR-T therapy.
- Cleveland Clinic: Key partner in Anixa’s vaccine portfolio for breast and ovarian cancers.
Corporate Developments
This update falls under 'Corporate Developments' as it highlights advancements in clinical trials and important collaborations, which are crucial for Anixa's market position and investor relations.